Mexiletine therapy in patients with chronic drug-resistant malignant ventricular arrhythmias. Clinical efficacy, safety, and side effects.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D001145:Arrhythmias, Cardiac / Q000188:drug therapy*; D002908:Chronic Disease; D003645:Death, Sudden / Q000209:etiology; D004244:Dizziness / Q000139:chemically induced; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D004562:Electrocardiography; D005260:Female; D006352:Heart Ventricles; D006801:Humans; D008297:Male; D008801:Mexiletine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D011437:Propylamines / Q000627:therapeutic use*; D013610:Tachycardia / Q000188:drug therapy; D014202:Tremor / Q000139:chemically induced; D014693:Ventricular Fibrillation / Q000188:drug therapy
D000319:Adrenergic beta-Antagonists; D011437:Propylamines; D008801:Mexiletine